Considering the prominent role of STAT3 signalling in the biology of cancer cells, these results provide further support to the therapeutic potential of IL-6R inhibition with tocilizumab in mucoepidermoid carcinoma. This evidence concerns the gene STAT3 and mucoepidermoid carcinoma.